The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...

The expression of PD-L1 and mismatch repair enzymes was evaluated in cases with available immunohistochemistry (IHC) data. These findings reinforce therapeutic efforts to target IDH signaling in ...

Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian ...

Covering primary, special, IHC, and ISH staining ... A Medical Affairs Symposium, “PD-L1 Heterogeneity Across the Patient Journey,” will also be held Monday, March 24, from 5:30–7:00 ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

1 A total of 594 (85%) of the 698 patients had tumors that expressed PD-L1 with a CPS ≥1 using the PD-L1 IHC 22C3 pharmDx kit. Once enrolled, patients were randomly assigned in a 1:1 fashion to ...

Joshua K. Sabari, MD, discusses whether individual B7-H3 analysis is available at his institution, noting that, if it is, he obtains IHC for both PD-L1 and B7-H3 expression levels in all patients with ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...